Gold Standard Diagnostics introduces ThunderBolt automated
12 August 2010
Gold Standard Diagnostics, Corp. (GSD), has introduced the
ThunderBolt platform, the company’s first automated instrumentation
offering for clinical and hospital laboratories.
The ThunderBolt platform will provide laboratory customers with a
single hardware solution that can utilize multiple diagnostics
technologies such as EIA, chemiluminescence and multiplexing.
The inaugural product of the ThunderBolt platform is an EIA
(enzyme immunoassay) processor, with a completely open software
design capable of programming virtually any EIA test. EIA tests are
widely used to detect and quantify substances such as peptides,
proteins, antibodies and hormones, and to diagnose diseases and
conditions including infections, cancer, metabolic disorders,
allergies and autoimmune diseases.
In a single, easily configured run, the flexible ThunderBolt EIA
processor can process multiple microtiter plates, while also running
up to eight different simultaneous assays. With an onboard reader,
the fully automated EIA processor offers a true “walkaway” solution
for labs of any size.
The compact design takes up less than half the workspace of
similar EIA automated processors on the market. Cost-effective
operation makes the ThunderBolt suitable for larger clinical
laboratories, while it also provides the customizable capabilities
needed in hospital or research laboratories.
“The ThunderBolt platform represents a true innovation in
automated diagnostics instrumentation and is the culmination of
nearly 20 years of feedback from laboratory customers around the
world,” says John Griffiths, president and CEO of Gold Standard
Diagnostics. “By understanding what customers really need, we have
been able to build a product that’s the right blend of power,
flexibility and ease of use, all at a competitive price.”